Calpain-2 as a therapeutic target in repeated concussion-induced neuropathy and behavioral impairment

Sci Adv. 2020 Jul 1;6(27):eaba5547. doi: 10.1126/sciadv.aba5547. Print 2020 Jul.

Abstract

Repeated concussion represents a serious health problem as it can result in various brain pathologies, ranging from minor focal tissue injury to severe chronic traumatic encephalopathy. The calcium-dependent protease, calpain, participates in the development of neurodegeneration following concussion, but there is no information regarding the relative contribution of calpain-1 and calpain-2, the major calpain isoforms in the brain. We used a mouse model of repeated concussions, which reproduces most of the behavioral and neuropathological features of the human condition, to address this issue. Deletion of calpain-2 or treatment with a selective calpain-2 inhibitor for 2 weeks prevented most of these neuropathological features. Changes in TAR DNA binding protein 43 (TDP-43) subcellular localization similar to those found in human amyotrophic lateral sclerosis and frontotemporal dementia were also prevented by deletion of calpain-2 or treatment with calpain-2 inhibitor. Our results indicate that a selective calpain-2 inhibitor represents a therapeutic approach for concussion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyotrophic Lateral Sclerosis
  • Animals
  • Brain / physiopathology
  • Brain Concussion* / complications
  • Brain Concussion* / drug therapy
  • Calpain* / antagonists & inhibitors
  • Calpain* / genetics
  • Frontotemporal Dementia
  • Mice

Substances

  • Calpain